Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma, Follicular × Thyrotropin Alfa × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Neoplasm Metastasis 1 Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 2 tremelimumab 1 gallium Ga 68 dotatate 1 durvalumab 1 cobimetinib 1 X-Rays 1 Vemurafenib 1 Thyrotropin Alfa 1 Specimen Handling 1 Iodine-131 1 High-Energy Shock Waves 1 Glycoprotein Hormones, alpha Subunit 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06440850 2026-02-02

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

City of Hope Medical Center

Phase 2 Recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡